Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al
- PMID: 32586919
- DOI: 10.1136/annrheumdis-2020-218179
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al
Keywords: antirheumatic agents; autoimmune diseases; epidemiology.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.Ann Rheum Dis. 2020 Sep;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888. Epub 2020 May 26. Ann Rheum Dis. 2020. PMID: 32457048 Free PMC article.
-
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25. Ann Rheum Dis. 2022. PMID: 32586922 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
